<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877717</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-A1904-I-101</org_study_id>
    <nct_id>NCT04877717</nct_id>
  </id_info>
  <brief_title>A Study of SHR-A1904 in Patients With Advanced Solid Cancer</brief_title>
  <official_title>An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1904 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Hengrui Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Hengrui Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients&#xD;
      with advanced solid cancer and to determine the dose-limiting toxicity (DLT), maximum&#xD;
      tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>SHR-A1904 monotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Maximum Tolerated Dose of SHR-A1904</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration-time curve from time 0 to the last measurable concentration time point (AUC0-t)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) of SHR-A1904</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Advanced Solid Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-A1904</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1904</intervention_name>
    <description>SHR-A1904</description>
    <arm_group_label>SHR-A1904</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the subject has been informed of all pertinent aspects of the study&#xD;
&#xD;
          2. Males or females aged 18-75 years old&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          4. Has a life expectancyâ‰¥ 3 months&#xD;
&#xD;
          5. Has at least one measurable lesion as defined by RECIST v1.1&#xD;
&#xD;
          6. Pathologically confirmed advanced solid cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Plan to receive any other anti-tumor treatments during the study treatment period of&#xD;
             this study&#xD;
&#xD;
          2. Received other clinical investigational products or treatments within 4 weeks before&#xD;
             the first dose of the study&#xD;
&#xD;
          3. Received anti-tumor therapies such as chemotherapy, radiotherapy, biological therapy,&#xD;
             targeted therapy, or immunotherapy within 4 weeks before the first dose of the study&#xD;
&#xD;
          4. Underwent a major surgery other than diagnosis or biopsy within 4 weeks before the&#xD;
             first dose of the study&#xD;
&#xD;
          5. Subjects with known brain metastases&#xD;
&#xD;
          6. Grade II-IV cardiac insufficiency as per the New York Heart Association (NYHA)&#xD;
             criteria; arrhythmia requiring long-term drug control; unstable angina or acute&#xD;
             myocardial infarction within 6 months before the first dose of the study&#xD;
&#xD;
          7. presence of accompanying diseases (such as poorly controlled hypertension, serious&#xD;
             diabetes mellitus, thyroid disorder, psychosis, etc.) that may pose serious risks to&#xD;
             the safety of the subject or may affect the subject's ability to complete the study,&#xD;
             or any other situation as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunlei Jin, Ph.D.</last_name>
    <phone>+86-021-23511999</phone>
    <email>chunlei.jin@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Hu</last_name>
    <phone>+86 18036618148</phone>
    <email>Liang.hu@hengrui.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

